FDA OKs Treatment for Severe Eosinophilic Asthma

Article

Officials with the FDA have approved benralizumab (Fasenra, AstraZeneca) for the add-on maintenance treatment of patients with severe eosinophilic asthma aged 12 years and older.

Officials with the FDA have approved benralizumab (Fasenra, AstraZeneca) for the add-on maintenance treatment of patients with severe eosinophilic asthma aged 12 years and older, according to a company press release.

The approval is based on data from clinical trials that evaluated 8-week benralizumab dosing regimens in patients with asthma. According to the press release, results from the data showed:

  • Up to 51% reduction in the annual exacerbation rate compared to a placebo.
  • Significant improvement in lung function as measured by forced expiratory volume in 1 second of up to 159mL versus placebo. Differences were seen as early as 4 weeks after the first dose, providing an early indication of effectiveness.
  • 75% median reduction in daily oral corticosteroid use (OCS) and discontinuation of OCS use in 52% of eligible patients.

With this approval, benralizumab is the only respiratory biologic that provides direct, rapid, and near-complete depletion of eosinophils within 24 hours. Elevated levels of eosinophils are seen in about half of patients with severe asthma, causing increased asthma severity and symptoms, decreased lung function, and increased risk of exacerbations. Benralizumab works by binding directly to the IL-5α receptor on an eosinophil and attracting natural killer cells to induce programmed cell death.

Benralizumab will be available as a once every 8-week fixed-dose subcutaneous injection via a prefilled syringe.

Reference

Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma [news release]. AstraZeneca’s website. https://www.astrazeneca.com/media-centre/press-releases/2017/fasenra-benralizumab-receives-us-fda-approval-for-severe-uncontrolled-eosinophilic-asthma-14112017.html. Accessed November 15, 2017.

Related Videos
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz - stock.adobe.com
Image credit: New Africa | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image Credit: Pixel-Shot | stock.adobe.com
Pharmacist holding medicine box and capsule pack in pharmacy drugstore. -- Image credit: I Viewfinder | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.